IVA Inventiva SA

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2025:

  • Cash: € 526,751.56
  • Number of shares: 58,515 
  • Number of executions on buy side on semester: 2,332
  • Number of executions on sell side on semester: 2,741
  • Traded volume on buy side on semester: 550,198 shares for € 2,093,559.19
  • Traded volume on sell side on semester: 576,215 shares for € 2,189,327.66

At the last half-year report as of 30 June 2025 the following resources were available in the liquidity account:

  • Cash: € 428,212.57
  • Number of shares: 84,532
  • Number of executions on buy side on semester: 1,642
  • Number of executions on sell side on semester: 1,878
  • Traded volume on buy side on semester: 267,584 shares for € 744,692.94
  • Traded volume on sell side on semester: 296,504 shares for € 819,771.51

When the contract was initially implemented, the following resources were included in the liquidity account:

  • Cash: € 163,510.42
  • Number of shares: 34,063
 Buy Side Sell Side
 Number of

executions		Number of

shares		Traded volume in EUR Number of

executions		Number of

shares		Traded volume in EUR
Total2,332550,1982,093,559.19 2,741576,2152,189,327.66
07/01/2025142,6136,846.06 101,2363,275.40
07/02/2025183,3728,699.76 ---
07/03/202591,5013,977.65 498,03721,378.42
07/04/2025172,9997,917.36 25001,325.00
07/07/2025211,5164,017.40 193,3428,923.14
07/08/202548372,293.38 375,72015,730.00
07/09/2025101,7504,830.00 212,5006,975.00
07/10/202557782,155.06 101,0012,782.78
07/11/202581,6074,467.46 161,9995,597.20
07/14/2025182,8787,885.72 55501,518.00
07/15/20253252690.48 202,5006,900.00
07/16/202571,4984,149.46 131,9775,515.83
07/17/20251250695.00 101,0232,843.94
07/18/202581,0002,760.00 4240669.60
07/21/2025152,2706,197.10 1250685.00
07/22/202561,0002,750.00 273,76010,377.60
07/23/2025335,73015,757.50 356,45017,995.50
07/24/202581,7504,742.50 ---
07/25/2025--- 41,0002,780.00
07/28/2025214,75013,347.50 427,75322,173.58
07/29/20252250725.00 7511,15432,346.60
07/30/2025274,53112,958.66 101,6154,731.95
07/31/2025203,96911,192.58 254,75013,585.00
08/01/2025172,7507,755.00 71,2513,590.37
08/04/2025112,5006,950.00 51,0312,876.49
08/05/2025131,7504,935.00 121,7194,864.77
08/06/2025111,9845,555.20 193,53910,050.76
08/07/2025213,0008,700.00 223,4119,994.23
08/08/2025122,0675,932.29 212,0495,962.59
08/11/2025102,0005,840.00 212,2506,592.50
08/12/20252279825.84 283,75011,137.50
08/13/2025222,9018,993.10 669,75030,615.00
08/14/202547502,527.50 6510,99937,396.60
08/15/2025183,75012,862.50 142,0507,154.50
08/18/202537502,535.00 345,70020,406.00
08/19/2025163,25012,382.50 679,00034,740.00
08/20/2025112,5009,650.00 143,04011,825.60
08/21/2025294,10815,651.48 163,46013,390.20
08/22/2025142,99211,459.36 101,7516,811.39
08/25/202571,7506,772.50 396,75027,067.50
08/26/2025142,75011,110.00 193,25013,292.50
08/27/2025--- 7512,25054,145.00
08/28/2025204,00019,320.00 387,00034,440.00
08/29/2025286,25029,500.00 405,75027,887.50
09/01/2025366,75031,792.50 101,5007,560.00
09/02/2025163,00013,260.00 102,25010,125.00
09/03/2025--- 275,00023,400.00
09/04/20253413,00058,760.00 ---
09/05/202563,95517,599.75 22,0009,000.00
09/08/20252712,00052,320.00 710,00044,000.00
09/09/202512,0008,900.00 810,00045,500.00
09/10/2025--- 34,00018,600.00
09/11/2025--- 31,0004,750.00
09/12/202547503,487.50 ---
09/15/202532,50011,300.00 22501,195.00
09/16/202543,50015,575.00 21,0004,500.00
09/17/202567,00030,170.00 54,00017,360.00
09/18/2025--- 123,00013,560.00
09/19/2025--- 42,0009,240.00
09/22/2025162,34510,904.25 183,25015,307.50
09/23/2025295,75027,025.00 326,50030,810.00
09/24/2025305,27824,912.16 163,50016,765.00
09/25/2025--- 346,95534,427.25
09/26/2025316,75033,075.00 336,25031,000.00
09/29/2025409,50046,930.00 357,00035,280.00
09/30/2025398,00038,560.00 203,75018,337.50
10/01/2025142,75113,554.95 336,25031,270.00
10/02/2025122,75013,970.00 387,33537,921.95
10/03/2025378,00042,640.00 416,25033,625.00
10/06/2025479,25047,452.50 131,5007,755.00
10/07/2025408,24941,162.51 243,75019,387.50
10/08/2025478,72240,470.08 203,04714,503.72
10/09/20254910,90046,216.00 356,00025,620.00
10/10/2025419,25037,185.00 274,75019,380.00
10/13/2025529,90038,412.00 122,75010,917.50
10/14/2025306,50023,855.00 5612,00046,200.00
10/15/2025378,00030,880.00 133,00011,760.00
10/16/2025275,75020,757.50 265,06918,856.68
10/17/2025306,25021,625.00 214,00013,960.00
10/20/2025306,75022,545.00 133,25010,985.00
10/21/2025153,50011,550.00 162,7509,212.50
10/22/2025296,60021,054.00 92,0006,400.00
10/23/2025234,89915,039.93 194,50013,950.00
10/24/2025184,00012,280.00 173,47410,977.84
10/27/2025133,0009,210.00 447,50023,325.00
10/28/2025133,25010,562.50 7213,52644,500.54
10/29/20255212,00039,600.00 9520,18174,669.70
10/30/2025478,75530,467.40 37502,625.00
10/31/202551,2504,500.00 336,75024,435.00
11/03/2025357,29526,043.15 264,57416,740.84
11/04/2025213,00510,547.55 347,17725,837.20
11/05/2025264,60616,489.48 92,2508,190.00
11/06/2025122,0507,646.50 397,50028,350.00
11/07/2025245,34419,398.72 51,2504,650.00
11/10/2025398,49529,052.90 47502,685.00
11/11/2025122,2507,312.50 ---
11/12/202561,5005,040.00 264,50015,210.00
11/13/202592,2507,245.00 37502,430.00
11/14/202592,2507,177.50 122,5008,325.00
11/17/2025102,5008,575.00 468,00028,080.00
11/18/2025223,75012,975.00 111,5005,235.00
11/19/2025143,00010,410.00 143,50012,285.00
11/20/2025172,7509,570.00 184,25015,130.00
11/21/2025284,89517,132.50 82,0007,100.00
11/24/2025132,8009,660.00 304,00014,000.00
11/25/2025153,30712,037.48 5110,00036,900.00
11/26/20253612,00045,960.00 3411,52045,388.80
11/27/2025176,50024,245.00 309,00034,110.00
11/28/2025214,44316,261.38 15001,850.00
12/01/202562,0007,240.00 41,0003,690.00
12/02/20252812,50046,750.00 177,50028,725.00
12/03/20254814,25549,607.40 ---
12/04/2025165,50019,140.00 145,00017,550.00
12/05/2025224,50015,705.00 72,5068,821.12
12/08/202592,5008,700.00 216,91224,192.00
12/09/2025125,00017,750.00 258,08229,014.38
12/10/2025236,20622,713.96 3111,06041,475.00
12/11/2025187,00026,180.00 165,00019,000.00
12/12/202552,0007,520.00 180308.80
12/15/2025269,00033,750.00 155,50020,900.00
12/16/2025239,29433,830.16 218,00129,523.69
12/17/2025136,00022,620.00 299,35935,844.97
12/18/2025188,00030,320.00 176,94327,216.56
12/19/2025229,50034,675.00 135,00018,450.00
12/22/2025216,50023,335.00 228,00029,280.00
12/23/2025227,50028,800.00 2910,49440,821.66
12/24/2025124,35316,280.22 104,00015,160.00
12/29/2025464239.36 133,56313,681.92
12/30/202551,0003,880.00 31,5005,910.00
12/31/202551,0003,870.00 25001,960.00

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.  

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).

Contacts

Inventiva



Pascaline Clerc, PhD

EVP, External and Corporate Affairs

   

    		ICR Healthcare

Alexis Feinberg

Media Relations







 		ICR Healthcare

Patricia L. Bank

Investor Relations

          



         

Attachment



EN
26/01/2026

Underlying

IVAInventiva SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inventiva SA

 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...

February 26, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva participera à quatre conférences investisseurs en mars

Inventiva participera à quatre conférences investisseurs en mars  Daix (France), New York (États-Unis), le 26 février 2026 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que la direction de la Société participera à des réunions individuelles et à des présentations lors des événements investisseurs suivants : TD Cowen 46ème Health Care Conference – 2 au 4 mars 2026Date : lun...

February 26, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...

February 26, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapie for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2...

February 26, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
IVA INVENTIVA SA

Inventiva FIRST LOOK: preliminary FY25 results hold no surprises

Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.

02/17/26 February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch